Even if Amarin prevails in its patent infringement lawsuit, its key patents on Vascepa are likely to be ruled invalid in ongoing litigation, opening the way for generic formulations.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Curfman, G. JAMA Intern. Med. 177, 194 (2017).
Manson, J. E. et al. N. Engl. J. Med. 380, 23–32 (2019).
Ballantyne, C. M. et al. Am. J. Cardiol. 110, 984–992 (2012).
Bays, H. E. et al. Am. J. Cardiol. 108, 682–690 (2011).
Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc. 033020 NVDC, 2:16-cv-02525-MMD-NJK.
Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc. et al. USCAFC 20-1723, doc 70, 9-30-2020.
US Food and Drug Administration. ANDA approval letter to Hikma Pharmaceuticals USA Inc. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/209457Orig1s000ltr.pdf, (2020).
Bhatt, D. L. et al. N. Engl. J. Med. 380, 11–22 (2019).
US Food and Drug Administration. Supplement approval letter to Amarin Pharma Inc. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/202057Orig1s035ltr.pdf, (2019).
Federal Food, Drug, and Cosmetic Act, Section 505(j)(2)(A)(viii).
US Food and Drug Administration. Preface, Orange Book, 42nd edn, https://www.fda.gov/drugs/development-approval-process-drugs/orange-book-preface, (2022).
Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc et al. C.A. No. 20-1630-RGA-JLH; https://www.ded.uscourts.gov/sites/ded/files/opinions/20-1630.pdf (August 2021).
Amarin Pharma v. Hikma Pharm. US. C.A. 20-1630-RGA-JLH (D. Del., https://casetext.com/case/amarin-pharma-v-hikma-pharmus, (January 2022).
Silbersher, Z. Will Amarin’s new cardiovascular patent lawsuit against Hikma keep out generic sales? Markman Advisors, https://www.markmanadvisors.com/blog/2020/12/2/will-amarins-new-cardiovascular-patent-lawsuit-against-hikma-keep-out-generic-sales (December 2020).
Yokoyama, M. et al. Lancet 369, 1090–1098 (2007).
Nicholls, S. J. et al. J. Am. Med. Assoc. 324, 2268–2280 (2020).
Gugliuzza, P. R. Iowa Law Rev. 106, 607–664 (2021).
35 USC § 103; https://www.law.cornell.edu/uscode/text/35/103
Graham v. John Deere Co. 383 US 1, 148 USPQ 459 (1966).
KSR International Co. v. Teleflex Inc. 550 US 398, 82 USPQ2d 1385 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Curfman, G., Cole, J. Vascepa patents under legal scrutiny. Nat Biotechnol 40, 829–831 (2022). https://doi.org/10.1038/s41587-022-01345-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01345-8